The aim of this study was to determine the risk factors associated with tuberculosis among human immunodeficiency virus (HIV)-infected persons living in Switzerland, a country with low prevalence of tuberculous infection. We performed a nested case-control study and logistic regression. Cases (n = 239) were patients participating in the Swiss-HIV Cohort study (n = 7,103), diagnosed with bacteriologically confirmed tuberculosis. The rest of the cohort population was used as control. Patients from industrialized countries had a risk of tuberculosis similar to those from Switzerland (adjusted odds ratio (OR) 1.1; 95% confidence interval (95% CI) 0.7-1.5); whereas the risk among patients from Eastern Europe (OR 2.8, 95% CI 1.9-3.7), Brazil (OR 10.6; 95% CI 9.6-11.5), and Africa (OR 3.0; 95% CI 2.4-3.6) was markedly higher. Immune suppression, as indicated by low CD4 + cell count, was an independent risk factor for tuberculosis (OR 7.8; 95% CI 7.3-8.3 for patients with CD4 + < 50 cells.mm-3 compared to those with CD4 + > 500 cells.mm-3). Age, sex and HIV-transmission category did not appear to increase the risk of tuberculosis after adjustment for other patient characteristics. In conclusion, in countries of low prevalence of Mycobacterium tuberculosis infection, to originate from a country with high prevalence of tuberculosis infection and to have advanced immunodeficiency are significant risk factors for tuberculosis. They may be used to complement the tuberculin skin test in targeting patients for preventive chemotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1183/09031936.96.09020279 | DOI Listing |
JAMA Netw Open
January 2025
Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Importance: Multisystem inflammatory syndrome in children (MIS-C) is an uncommon but severe hyperinflammatory illness that occurs 2 to 6 weeks after SARS-CoV-2 infection. Presentation overlaps with other conditions, and risk factors for severity differ by patient. Characterizing patterns of MIS-C presentation can guide efforts to reduce misclassification, categorize phenotypes, and identify patients at risk for severe outcomes.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
Importance: Clinical trials are vital for advancing cancer treatments and improving patient outcomes. Understanding the factors that influence participants' decision-making is critical for enhancing trial recruitment.
Objective: To evaluate the attitudes of patients with cancer and their relatives toward clinical trial participation, identifying key barriers and motivators that affect their willingness to engage in such trials.
Asian Pac J Cancer Prev
January 2025
Cancer Foundation of India, Kolkata, West Bengal, India.
Objective: The case-control study aims to identify the potential risk and protective factors contributing to breast cancer risk in the high-incidence Aizawl population and the low-incidence Agartala population, using age-specific prevalence data of established reproductive factors and body mass index (BMI) among healthy women.
Methods: A risk profile survey was conducted on asymptomatic women aged 30-64 in Aizawl and Agartala towns. Data was analysed using SPSS software.
Asian Pac J Cancer Prev
January 2025
Department of Physics, Faculty of Sciences, Arak University, Arak, Iran.
Objective: Addressing the rising cancer rates through timely diagnosis and treatment is crucial. Additionally, cancer survivors need to understand the potential risk of developing secondary cancer (SC), which can be influenced by several factors including treatment modalities, lifestyle choices, and habits such as smoking and alcohol consumption. This study aims to establish a novel relationship using linear regression models between dose and the risk of SC, comparing different prediction methods for lung, colon, and breast cancer.
View Article and Find Full Text PDFAsian Pac J Cancer Prev
January 2025
Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital Yogyakarta, Indonesia.
Background: Cancer cachexia in breast cancer (BC) patients is not commonly reported, particularly in Indonesia. This study assessed the prevalence of cachexia in local patients with BC receiving chemotherapy, and the associated factors.
Methods: This cross-sectional study included 160 BC patients who started chemotherapy between July 2018 and June 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!